IP Library › Granted Patent US 12,264,815
Granted Patent B2
US 12,264,815 · App. 17/970,156 · Granted Apr 1, 2025

Method of providing doses of light sufficient to deactivate dangerous pathogens throughout a volumetric space over a period of time

Inventors: James W. Hawkins (Lake Forest, IL); Clifford J. Yahnke (Kenosha, WI)
Assignee: LEGRAND LIGHTING MANUFACTURING CO.
F21V5/04A61L2/084A61L2/24A61L9/18A61L9/20A61N5/06F21K9/00F21S8/026F21V7/00F21V19/006F21V23/0442F21V23/0471F21V29/70F21V33/0068H01L33/50H05B45/20H05B45/56H05B47/10H05B47/105H05B47/175H05B47/19A61L2202/11A61L2202/14A61L2202/25A61L2209/111A61L2209/12A61N5/0624A61N2005/0662F21V15/01F21V23/06F21V31/005F21W2131/20F21Y2101/00F21Y2105/10F21Y2113/00F21Y2113/13F21Y2115/10H01L33/505H05B47/13H05B47/165H05B47/17
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,264,815
App. No.
17/970,156
Granted
Apr 1, 2025
Kind
B2
Abstract

A method of inactivating one or more pathogens in an environment. The method includes providing light from at least one lighting element of a lighting device installed in the environment, the at least one lighting element configured to provide light toward a target area in the environment, the provided light having at least a pathogen-inactivating first component in a first range of wavelengths of 400 nanometers to 420 nanometers. The pathogen-inactivating first component of light produces an irradiance of at least 0.01 mW/cm 2 as measured at a surface in the target area that is unshielded from the lighting device and located at a distance of 1.5 meters from an external-most luminous surface of the lighting device. Providing the light causes the one or more pathogens to be inactivated.

Claims (29)

1. A method of inactivating one or more pathogens in an environment, the method comprising:

providing light from at least one lighting element of a lighting device installed in the environment, the at least one lighting element configured to provide light toward a target area in the environment, the provided light having at least a pathogen-inactivating first component in a first range of wavelengths of 400 nanometers to 420 nanometers,

wherein the pathogen-inactivating first component of light produces an irradiance of at least 0.01 mW/cm 2 as measured at a surface in the target area that is unshielded from the lighting device and located at a distance of 1.5 meters from an external-most luminous surface of the lighting device,

wherein providing the light causes the one or more pathogens to be inactivated,

wherein the provided light is white light having u′, v′ coordinates on the 1976 CIE Chromaticity Diagram that lie within an area that is bounded (i) vertically between 0.035 Duv below and 0.035 Duv above a planckian locus defined by the ANSI C78.377-2015 color standard, and (ii) horizontally between a correlated color temperature (CCT) isoline of between approximately 1500K and 7000K.

2. The method of claim 1 , wherein the one or more pathogens are inactivated without using any photosensitizers to cause inactivation of the one or more pathogens.

3. The method of claim 1 , wherein the irradiance is substantially equal to 0.02, 0.05, 0.1 mW/cm 2 , 0.15 mW/cm 2 , 0.2 mW/cm 2 , 0.25 mW/cm 2 , or 0.3 mW/cm 2 at the surface in the target area that is unshielded from the lighting device and located at a distance of 1.5 meters from an external-most luminous surface of the lighting device.

4. The method of claim 1 , wherein the at least one lighting element comprises at least one light-emitting diode (LED).

5. The method of claim 4 , wherein the light is provided from the lighting device that further comprises a means for maintaining a junction temperature of the at least one LED below a maximum operating temperature of the at least one LED.

6. The method of claim 1 , wherein the light is provided from the at least one lighting element that comprises:

one or more first light-emitting elements configured to emit the pathogen-inactivating first component of the light; and

one or more second light-emitting elements configured to emit a second component of the provided light, such that providing light from the at least one lighting element comprises providing a combined light formed by the first component of light in combination with the second component of light.

7. The method of claim 1 , wherein the area is bounded vertically between 0.007 Duv below and 0.007 Duv above the planckian locus.

8. The method of claim 1 , wherein the light is provided from the at least one lighting element that comprises:

one or more light-emitting elements configured to emit the pathogen-inactivating first component of the light; and

one or more light-converting elements arranged with respect to the one or more light-emitting elements such that (1) a first portion of the pathogen-inactivating first component of the light is not altered by the one or more light-converting elements, and (2) a second portion of the pathogen-inactivating first component of the light passes through the one or more light-converting elements to produce a second component of the provided light, the second component having a wavelength of greater than 420 nm,

such that providing light from the at least one lighting element comprises providing a combined light formed by the first component of light in combination with the second component of light.

9. The method of claim 8 , wherein the area is bounded vertically between 0.007 Duv below and 0.007 Duv above the planckian locus.

10. The method of claim 8 , wherein the one or more light-converting elements include one or more phosphors.

11. The method of claim 1 , wherein the at least one lighting element is contained within a housing.

12. The method of claim 1 , wherein the light is provided over an operating mode of eight hours or 24 hours over which the lighting device is configured to irradiate the target area.

13. A method of inactivating one or more pathogens in an environment, the method comprising:

providing light from at least one lighting element of a lighting device installed in the environment, the at least one lighting element configured to provide light toward a target area in the environment, the provided light having at least a pathogen-inactivating first component in a first range of wavelengths of 400 nanometers to 420 nanometers,

wherein the pathogen-inactivating first component of light produces an irradiance of at least 0.01 mW/cm 2 as measured at a surface in the target area that is unshielded from the lighting device and located at a distance of 1.5 meters from an external-most luminous surface of the lighting device,

wherein providing the light causes the one or more pathogens to be inactivated,

and wherein the light is provided from the at least one lighting element that comprises:

one or more light-emitting elements configured to emit the pathogen-inactivating first component of the light; and

one or more light-converting elements arranged with respect to the one or more light-emitting elements such that (1) a first portion of the pathogen-inactivating first component of the light is not altered by the one or more light-converting elements, and (2) a second portion of the pathogen-inactivating first component of the light passes through the one or more light-converting elements to produce a second component of the provided light, the second component having a wavelength of greater than 420 nm,

such that providing light from the at least one lighting element comprises providing a combined light formed by the first component of light in combination with the second component of light.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Dec 3, 2024
From: PINNACLE ARCHITECTURAL LIGHTING, INC.; KENALL MANUFACTURING CO.
To: LEGRAND LIGHTING MANUFACTURING CO.
Reel/Frame 069475/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2022
From: HAWKINS, JAMES W.; YAHNKE, CLIFFORD J.
To: KENALL MANUFACTURING COMPANY
Reel/Frame 061544/0986 →
Continuity (7)
Continuation 16368755 · Mar 28, 2019
Continuation 16027829 · Jul 5, 2018
Continuation 15485926 · Apr 12, 2017
Continuation 15178349 · Jun 9, 2016
Provisional Application 62190113 · Jul 8, 2015
Provisional Application 62185391 · Jun 26, 2015
Related Publication 20230051102A1 · Feb 16, 2023
References Cited (149)
US 3670193A · Thorington et al. · 1972 [cited by applicant]
US 3992646A · Corth · 1976 [cited by applicant]
US 5189393A · Hu · 1993 [cited by applicant]
US 6242752B1 · Soma et al. · 2001 [cited by applicant]
US 6791259B1 · Stokes et al. · 2004 [cited by applicant]
US 7658891B1 · Barnes · 2010 [cited by applicant]
US 8398264B2 · Anderson et al. · 2013 [cited by applicant]
US 8476844B2 · Hancock et al. · 2013 [cited by applicant]
US 8508204B2 · Deurenberg et al. · 2013 [cited by applicant]
US 9039966B2 · Anderson et al. · 2015 [cited by applicant]
US 9046227B2 · David et al. · 2015 [cited by applicant]
US 9368695B2 · David et al. · 2016 [cited by applicant]
US 9439989B2 · Lalicki et al. · 2016 [cited by applicant]
US 9581310B2 · Wu et al. · 2017 [cited by applicant]
US 9700641B2 · Hawkins et al. · 2017 [cited by applicant]
US 10363325B2 · Hawkins et al. · 2019 [cited by applicant]
US 11054109B2 · Hawkins et al. · 2021 [cited by applicant]
US 11054110B2 · Hawkins et al. · 2021 [cited by applicant]
US 11324843B2 · Hawkins et al. · 2022 [cited by applicant]
US 11493183B2 · Hawkins et al. · 2022 [cited by applicant]
US 20020175815A1 · Baldwin · 2002 [cited by applicant]
US 20030124023A1 · Burgess et al. · 2003 [cited by applicant]
US 20040008523A1 · Butler · 2004 [cited by applicant]
US 20050040772A1 · Guzman et al. · 2005 [cited by applicant]
US 20050055070A1 · Jones et al. · 2005 [cited by applicant]
US 20050207159A1 · Maxik · 2005 [cited by applicant]
US 20060022582A1 · Radkov · 2006 [cited by applicant]
US 20060071589A1 · Radkov · 2006 [cited by applicant]
US 20060104859A1 · Tribelsky · 2006 [cited by applicant]
US 20060186377A1 · Takahashi et al. · 2006 [cited by applicant]
US 20060262545A1 · Piepgras et al. · 2006 [cited by applicant]
US 20070231188A1 · Jung et al. · 2007 [cited by applicant]
US 20080008620A1 · Alexiadis · 2008 [cited by applicant]
US 20080232085A1 · Luettgens et al. · 2008 [cited by applicant]
US 20080278927A1 · Li et al. · 2008 [cited by applicant]
US 20080305004A1 · Anderson et al. · 2008 [cited by applicant]
US 20090002976A1 · Schulz · 2009 [cited by applicant]
US 20090034236A1 · Reuben · 2009 [cited by applicant]
US 20090225640A1 · Manabe et al. · 2009 [cited by applicant]
US 20090231832A1 · Zukauskas et al. · 2009 [cited by applicant]
US 20100001648A1 · De Clercq et al. · 2010 [cited by applicant]
US 20100232135A1 · Munehiro et al. · 2010 [cited by applicant]
US 20100246169A1 · Anderson et al. · 2010 [cited by applicant]
US 20120281408A1 · Owen et al. · 2012 [cited by applicant]
US 20120320607A1 · Kinomoto et al. · 2012 [cited by applicant]
US 20130077299A1 · Hussell et al. · 2013 [cited by applicant]
US 20130234041A1 · Deal · 2013 [cited by applicant]
US 20130287627A1 · Livchak et al. · 2013 [cited by applicant]
US 20130313516A1 · David et al. · 2013 [cited by applicant]
US 20130313546A1 · Yu · 2013 [cited by applicant]
US 20130330235A1 · Stibich et al. · 2013 [cited by applicant]
US 20140212332A1 · Bergman · 2014 [cited by applicant]
US 20140254131A1 · Osinski et al. · 2014 [cited by applicant]
US 20140301062A1 · David et al. · 2014 [cited by applicant]
US 20140328046A1 · Aanegola et al. · 2014 [cited by applicant]
US 20150062907A1 · Ng et al. · 2015 [cited by applicant]
US 20150086420A1 · Trapani · 2015 [cited by applicant]
US 20150129781A1 · Kretschmann · 2015 [cited by applicant]
US 20150182646A1 · Anderson et al. · 2015 [cited by applicant]
US 20150359922A1 · Kim et al. · 2015 [cited by applicant]
US 20160015840A1 · Gordon · 2016 [cited by applicant]
US 20160030609A1 · Peterson et al. · 2016 [cited by applicant]
US 20160030610A1 · Peterson et al. · 2016 [cited by applicant]
US 20160135271A1 · Alexander · 2016 [cited by applicant]
US 20160271281A1 · Clynne et al. · 2016 [cited by applicant]
US 20160273717A1 · Krames et al. · 2016 [cited by applicant]
US 20160276550A1 · David et al. · 2016 [cited by applicant]
US 20160375161A1 · Hawkins et al. · 2016 [cited by applicant]
US 20160375162A1 · Marry et al. · 2016 [cited by applicant]
US 20160375163A1 · Hawkins et al. · 2016 [cited by applicant]
US 20170014538A1 · Rantala · 2017 [cited by applicant]
US 20180243452A1 · Hawkins et al. · 2018 [cited by applicant]
US 20180243453A1 · Hawkins et al. · 2018 [cited by applicant]
US 20180311386A1 · Hawkins et al. · 2018 [cited by applicant]
US 20180311387A1 · Hawkins et al. · 2018 [cited by applicant]
US 20180326104A1 · Hawkins et al. · 2018 [cited by applicant]
US 20190083667A1 · Hawkins et al. · 2019 [cited by applicant]
US 20190216957A1 · Hawkins et al. · 2019 [cited by applicant]
US 20190224350A1 · Marry et al. · 2019 [cited by applicant]
US 20190298867A1 · Barron et al. · 2019 [cited by applicant]
CN 101248534A · 2008 [cited by applicant]
CN 101331430A · 2008 [cited by applicant]
CN 201244218Y · 2009 [cited by applicant]
CN 104421710A · 2015 [cited by applicant]
EP 1693016A1 · 2006 [cited by applicant]
EP 1887298A1 · 2008 [cited by applicant]
EP 1943880B1 · 2013 [cited by applicant]
JP 2003332620A · 2003 [cited by applicant]
JP 2003339845A · 2003 [cited by applicant]
JP 2008079510A · 2008 [cited by applicant]
JP 2008263249A · 2008 [cited by applicant]
JP 2010207278A · 2010 [cited by applicant]
JP 2014125692A · 2014 [cited by applicant]
JP 2014210922A · 2014 [cited by applicant]
WO WO0114012A1 · 2001 [cited by applicant]
WO WO03063902A2 · 2003 [cited by applicant]
WO WO2004033028A2 · 2004 [cited by applicant]
WO WO2006100303A2 · 2006 [cited by applicant]
WO WO2006126482A1 · 2006 [cited by applicant]
WO WO2007012875A1 · 2007 [cited by applicant]
WO WO2009056838A1 · 2009 [cited by applicant]
WO WO2015035425A1 · 2015 [cited by applicant]
WO WO2015066099A2 · 2015 [cited by applicant]
WO WO2016019029A1 · 2016 [cited by applicant]
WO WO2017205578A1 · 2017 [cited by applicant]
“Continuous Environmental Disinfection in the OR: A Case Study”, Maury Regional Medical Center (publicly available as of the filing date of application). [cited by applicant]
Australian Patent Application No. 2016283968, Examination Report No. 1, dated Aug. 15, 2018. [cited by applicant]
Australian Patent Application No. 2016283970, Examination Report No. 1, dated Jan. 21, 2020. [cited by applicant]
Australian Patent Application No. 2016283970, Examination Report No. 2, dated Sep. 10, 2020. [cited by applicant]
Bache et al., “Clinical studies of the High-Intensity Narrow-Spectrum light Environmental Decontamination System (HINS-light EDS), for continuous disinfection in the burn unit inpatient and outpatient settings”, Burns, … [cited by applicant]
Bumah et al., Wavelength and bacterial density influence the bactericidal effect of blue light on methicillin-resistant [cited by applicant]
Chinese Patent Application No. 201680037376.7, First Office Action, dated May 17, 2019. [cited by applicant]
Chinese Patent Application No. 2016800374539, First Office Action, dated Nov. 8, 2019. [cited by applicant]
Chinese Patent Application No. 2016800374539, Second Office Action, issued Jul. 24, 2020. [cited by applicant]
Color Phenomena, “CIE-1931 Chromaticity Diagram”, 2010, retrieved from www.color-theory-phenomena.n1/10.02.htm on Jun. 7, 2017, 3 pages. [cited by applicant]
Dai et al., “Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond?”, Drug Resist Updat., 15(4): 223-236 (2012). [cited by applicant]
Edmiston, Air contamination and SSI risk—do we need a new standard?, Session 2207, APIC 2018, Minneapolis, Minnesota (Jun. 14, 2018). [cited by applicant]
European patent application No. 16738239.9, Office Action, mailed Apr. 29, 2021. [cited by applicant]
Guffey et al., In vitro bactericidal effects of 405-nm and 470-nm blue light, Photomedicine and Laser Surgery, 24(6):684-8 (2006). [cited by applicant]
Halstead et al., “Antibacterial activity of blue light against nosocomial wound pathogens growing planktonically and as mature biofilms”, Appl Environ Microbiol., 82(13):4006-16 (2016). [cited by applicant]
International Preliminary Report on Patentability, International Application No. PCT/GB2008/003679 mailing date May 4, 2010. [cited by applicant]
International Search Report and Written Opinion, International Application No. PCT/GB2008/003679 mailing date Mar. 3, 2009. [cited by applicant]
International Search Report and Written Opinion, International Application No. PCT/US2015/042678 mailing date Nov. 2, 2015. [cited by applicant]
International Search Report and Written Opinion, International Application No. PCT/US2016/044634 mailing date Oct. 20, 2016. [cited by applicant]
International Search Report for Application No. PCT/US2016/036704 dated Dec. 8, 2016. [cited by applicant]
International Search Report for Application No. PCT/US2016/036710 dated Dec. 8, 2016. [cited by applicant]
International Search Report for Application No. PCT/US2016/036722 dated Nov. 8, 2016. [cited by applicant]
Japanese patent application No. 2018-519679, Office Action, dated Apr. 23, 2019. [cited by applicant]
Japanese Patent Application No. 2018-519679, Office Action, dated Dec. 24, 2019. [cited by applicant]
LEDs Magazine, “ANSI continues advancements on SSL chromaticity standard”. Retrieved from the Internet on Aug. 2, 2016 at: <URL:<http://www.ledsmagazine.com/articles/print/volume12/issue-11/features/standards/ansi-conti… [cited by applicant]
LEDs Magazine, “ANSI evaluates revisions to SSL chromaticity standard”. Retrieved from the Internet on Aug. 2, 2016 at: <URL:<http://www.ledsmagazine.com/articles/2011/07/ansi-evaluates-revisions-to-ssl-chromaticity-sta… [cited by applicant]
LEDs Magazine, “ANSI works to update the solid-state lighting standard for chromaticity”. Retrieved from the Internet on Aug. 2, 2016 at: <URL:<http://www.ledsmagazine.com/articles/print/volume12/issue-2/features/standa… [cited by applicant]
LEDs Magazine, “Lumination Vio LED combines 405 nm chip with new phosphors”. Retrieved from the Internet on Aug. 2, 2016 at: <URL:<http://www.ledsmagazine.com/articles/2007/06/lumination-vio-led-combines-405-nm-chip-wit… [cited by applicant]
Loftus et al., Methicillin-resistant [cited by applicant]
Loftus et al., Multiple reservoirs contribute to intraoperative bacterial transmission, Anesth. Analg., 114(6):1236-48 (Jun. 2012). [cited by applicant]
Loftus et al., The dynamics and implications of bacterial transmission events arising from the anesthesia work area, Anesth. Analg., 120(4):853-60 (Apr. 2015). [cited by applicant]
Loftus et al., Transmission of pathogenic bacterial organisms in the anesthesia work area, Anesthesiology, 109(3):399-407 (Sep. 2008). [cited by applicant]
McDonald et al., “405 nm Light exposure of osteoblasts and inactivation of bacterial isolates from arthroplasty patients: potential for new disinfection applications?”, European Cells and Materials, 25:204-14 (2013). [cited by applicant]
Parvizi et al., Environment of care: Is it time to reassess microbial contamination of the operating room air as a risk factor for surgical site infection in total joint arthroplasty?, Am. J. Infection Control, 45:1267-… [cited by applicant]
Soraa, “PAR30L 18.5W”, Retrieved from the Internet on Aug. 2, 2016 at: <URL:http://www.soraa.com/products. [cited by applicant]
Soraa, “PAR30L”. Retrieved from the Internet on Aug. 2, 2016 at: <URL:<http://www.soraa.com/products/22-PAR30L>. [cited by applicant]
Speier et al., Color temperature tunable white light LED system, Proc. SPIE 6337, Sixth International Conference on Solid State Lighting, 63371F (Sep. 12, 2006). [cited by applicant]
Tomb et al., “Inactivation of Streptomyces phage ?C31 by 405 nm light”, Bacteriophage, 4:e32129-1-6 (2014). [cited by applicant]
Tsukada et al., “Bactericidal action of photo-irradiated aqueous extracts from the residue of crushed grapes from winemaking”, Biocontrol Science, 21(2): 113-121 (2016). [cited by applicant]
Written Opinion for Application No. PCT/US2016/036704 dated Dec. 8, 2016. [cited by applicant]
Written Opinion for Application No. PCT/US2016/036704 dated May 29, 2017. [cited by applicant]
Written Opinion for Application No. PCT/US2016/036710 dated Dec. 8, 2016. [cited by applicant]
Written Opinion for Application No. PCT/US2016/036722 dated Nov. 8, 2016. [cited by applicant]
Yezli et al., Surface contamination in operating rooms: a risk for transmission of pathogens?, Surg. Infect. (Larchmt), 15(6):694-9 (Dec. 2014). [cited by applicant]